Drug intelligence / Profile preview

xiyanping + mannitol + methylprednisolone + immunoglobulin

Development stage
Unknown
Lead developer
Jiangxi Qingfeng Pharmaceutical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

A combination therapy containing **xiyanping**, **mannitol**, **methylprednisolone**, and **immunoglobulin**, used for intensive anti-inflammatory, immunomodulatory, antiviral, and supportive purposes. - **Xiyanping** is a semi-synthetic injectable preparation from *Andrographis paniculata* mainly used in China, with active components including andrographolide sulfates. It is traditionally used for its antiviral, antibacterial, anti-inflammatory, and antitoxic effects, often in the treatment of upper respiratory tract infections, viral pneumonia, and as adjuvant therapy in COVID-19[3][5][1][9][7]. - **Mannitol** is an osmotic diuretic commonly used to reduce intracranial and intraocular pressure and as a renal function diagnostic aid. - **Methylprednisolone** is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, indicated for a broad range of autoimmune, allergic, and inflammatory disorders[2][4][6][8][10]. - **Immunoglobulin (IVIG)** is typically used for immune modulation and as replacement therapy in immune deficiencies or certain autoimmune diseases. This combination is likely employed in severe infections or immune-mediated disease states requiring management of inflammation, edema, immunosuppression, and immune support, though it does not represent a single registered product with a unique brand or formulation.

02

Targets

AQP1 (Aquaporin-1)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on xiyanping + mannitol + methylprednisolone + immunoglobulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on xiyanping + mannitol + methylprednisolone + immunoglobulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call